Discounted Cash Flow (DCF) Analysis Unlevered

Generation Bio Co. (GBIO)

$3.92

-0.01 (-0.25%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 3.92 | undervalue

Operating Data

Year
A/P
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 0.04---------
Revenue (%)
EBITDA -35.46---------
EBITDA (%)
EBIT -35.80---------
EBIT (%)
Depreciation 0.35---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash 74.87---------
Total Cash (%)
Account Receivables 1.29---------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable 1.68---------
Accounts Payable (%)
Capital Expenditure -3.02---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 3.92
Beta 1.966
Diluted Shares Outstanding 58.11
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.56%
Risk-Free Rate
Market Risk Premium
Cost of Equity 12.971
Total Debt 81.71
Total Equity 227.81
Total Capital 309.52
Debt Weighting 26.40
Equity Weighting 73.60
Wacc

Build Up Free Cash

Year
A/P
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 0.04---------
EBITDA -35.46---------
EBIT -35.80---------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT -35.80---------
Depreciation 0.35---------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -3.02-19.99-5.52-5.96-8.80-----
UFCF -38.48---------
WACC
PV UFCF ---------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 11.01
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -11.46
Equity Value -
Shares Outstanding 58.11
Equity Value Per Share -